Local generic drug giant Mylan is among six drugmakers being sued by attorneys general in 20 states, including Pennsylvania, for allegedly conspiring to fix drug prices.

The antitrust lawsuit, filed Thursday in federal court in Connecticut, alleges the drug companies’ actions reduced competition and led to artificially higher prices for two generic drugs: doxycycline hyclate delayed release, which is an antibiotic used to treat severe acne, and glyburide, an oral diabetes medication.

That suit came one day after the U.S. Justice Department unsealed documents charging two former executives of Heritage Pharmaceuticals in New Jersey of conspiring to fix prices on the same two drugs. The justice department’s probe, reportedly involving more than a dozen companies, is expected to produce additional charges. Mylan has acknowledged receiving a subpoena from the justice department about doxycycline.

The states’ investigation, which is ongoing into a number of additional drugs, “uncovered evidence of a broad, well-coordinated and long running series of conspiracies to fix prices,” according to a news release from Pennsylvania Attorney General Bruce Beemer.

Advertise with us

The complaint alleges that the misconduct was conceived and carried out by senior drug company executives and their subordinate marketing and sales executives.

The suit also contends that the drug companies knew their conduct was illegal and made efforts to avoid communicating with each other in writing, or in some instances, to delete written electronic communications after becoming aware of the investigation.

Mylan, which is run from executive offices in Cecil, did not respond to emails Thursday seeking comment. A spokeswoman told other media that the company knew of no evidence that it participated in price fixing.

Mylan had previously disclosed in government filings that it received a subpoena in late 2015 from the Connecticut attorney general’s office seeking pricing information for certain generic drugs as well as communications with competitors.

The other drug companies named in the suit were Teva Pharmaceuticals USA, Heritage Pharmaceuticals, Aurobindo Pharma USA, Citron Pharma and Mayne Pharma.

Advertise with us

The complaint described a cozy relationship between generic drug companies that included frequent “opportunities to meet and collude” during dinners, social events and private meetings.

It called Heritage the “ringleader of the conspiracies,” organizing the price fixing with “knowing and willing participants.”

Prices were fixed in two chief ways, according to the suit. In one, companies would agree on market share and avoid competing on bids to maintain prices.

In another, they would collectively agree to raise prices for a particular drug.

The suit described one alleged deal in 2013 between Heritage and Mylan, saying the companies avoided a price war for doxycycline by Mylan agreeing to “walk away” from at least one national wholesaler and one large pharmacy chain to allow Heritage to gain market share.

Advertise with us

Because Mylan and Heritage were the only two companies selling the generic drug at that time, pricing for it was still very profitable, the suit said.

“Companies that collude and fix prices for generic drugs in order to pad their profits must be held accountable for the very real harm they inflict,” said Eric Schneiderman, attorney general in New York, another of the 20 states in the case.

Spiraling drug prices on a number of products have triggered a public backlash and intense criticism on Capitol Hill in recent years.

Mylan landed in lawmakers’ crosshairs this summer amid cries of price-gouging for upping the list price of its EpiPen emergency allergy shot from around $100 a two-pack in 2009 to about $600.

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.